|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5245 USD | -3.19% |
|
-4.62% | +5.32% |
| Capitalization | 18.32M 15.79M 14.7M 13.68M 25.48M 1.66B 27.41M 169M 66.67M 793M 68.68M 67.27M 2.89B | P/E ratio 2025 * |
-1.54x | P/E ratio 2026 * | -4.77x |
|---|---|---|---|---|---|
| Enterprise value | 18.32M 15.79M 14.7M 13.68M 25.48M 1.66B 27.41M 169M 66.67M 793M 68.68M 67.27M 2.89B | EV / Sales 2025 * |
0.28x | EV / Sales 2026 * | 0.19x |
| Free-Float |
84.49% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | -3.19% | ||
| 1 week | -4.62% | ||
| Current month | +5.32% | ||
| 1 month | +4.50% | ||
| 3 months | -51.88% | ||
| 6 months | +16.35% | ||
| Current year | +5.32% |
| 1 week | 0.42 | 0.58 | |
| 1 month | 0.42 | 0.58 | |
| Current year | 0.42 | 0.58 | |
| 1 year | 0.28 | 1.32 | |
| 3 years | 0.28 | 7.44 | |
| 5 years | 0.28 | 225 | |
| 10 years | 0.28 | 312.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Grigorios Siokas
CEO | Chief Executive Officer | 60 | 25/02/2016 |
George Terzis
DFI | Director of Finance/CFO | 44 | 10/11/2020 |
| Chief Operating Officer | - | 31/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 12/01/2014 | |
Grigorios Siokas
CHM | Chairman | 60 | 25/02/2016 |
John Hoidas
BRD | Director/Board Member | 60 | 17/11/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.19% | -4.62% | -37.19% | -86.34% | 18.32M | ||
| -0.43% | +2.99% | +41.21% | +120.13% | 104B | ||
| -0.47% | +5.64% | +67.24% | +176.38% | 50.48B | ||
| +1.40% | +0.35% | - | - | 22.28B | ||
| -0.54% | -2.40% | +17.07% | -21.49% | 9.71B | ||
| -1.03% | -2.91% | -11.34% | -7.31% | 8.35B | ||
| +0.88% | -0.29% | +0.83% | +2.84% | 8.25B | ||
| +3.15% | +3.75% | +15.43% | +75.38% | 6.95B | ||
| -0.51% | -0.15% | +25.78% | +31.33% | 6.1B | ||
| Average | -0.08% | +0.27% | +14.88% | +36.36% | 23.99B | |
| Weighted average by Cap. | -0.12% | +2.68% | +41.38% | +112.77% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 64.4M 55.52M 51.68M 48.12M 89.59M 5.84B 96.39M 595M 234M 2.79B 242M 237M 10.18B | 98.6M 85M 79.13M 73.67M 137M 8.95B 148M 910M 359M 4.27B 370M 362M 15.58B |
| Net income | - | - |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
149
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 0.5245 $ | -3.19% | 1,144,658 |
| 15/01/26 | 0.5418 $ | +21.53% | 6,804,605 |
| 14/01/26 | 0.4458 $ | -4.66% | 2,573,529 |
| 13/01/26 | 0.4676 $ | -7.15% | 1,544,030 |
| 12/01/26 | 0.5036 $ | -8.42% | 990,680 |
Delayed Quote Nasdaq, January 16, 2026 at 09:00 pm
More quotesQuarterly revenue - Rate of surprise
- Stock Market
- Equities
- COSM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















